STOCK TITAN

10x Genomics to Report First Quarter 2023 Financial Results on May 3, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

10x Genomics (NASDAQ: TXG) announced it will release its first quarter 2023 financial results on May 3, 2023, after market close. A conference call will follow at 1:30 PM PT to discuss the results and future outlook.

The company, a leader in life sciences, provides products for analyzing biological systems, with a significant presence in top global research institutions and pharmaceutical companies. 10x Genomics boasts a portfolio of over 1,750 patents and its products are widely cited in scientific literature.

Positive
  • None.
Negative
  • None.

PLEASANTON, Calif., April 12, 2023 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced it will report financial results for the first quarter 2023 after market close on Wednesday, May 3, 2023. The company will host a conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.  The news release with the financial results will be accessible from the company's website prior to the conference call.

Live audio of the webcast will be available on the "Investors" section of the company website at: www.10xgenomics.com. The webcast will be archived and available for replay for at least 45 days after the event.

About 10x Genomics

10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health. Our integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. 10x Genomics products have been adopted by researchers around the world including in all of the top 100 global research institutions as ranked by Nature in 2021 based on publications and all of the top 20 global pharmaceutical companies by 2021 research and development spend and have been cited in over 4,500 research papers on discoveries ranging from oncology to immunology and neuroscience. Our patent portfolio comprises more than 1,750 issued patents and patent applications.

Disclosure Information

10x Genomics uses filings with the Securities and Exchange Commission, its website (www.10xgenomics.com), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Contacts 
Investors: investors@10xgenomics.com 
Media: media@10xgenomics.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-to-report-first-quarter-2023-financial-results-on-may-3-2023-301796025.html

SOURCE 10x Genomics, Inc.

FAQ

When will 10x Genomics report Q1 2023 financial results?

10x Genomics will report its Q1 2023 financial results on May 3, 2023.

What time is the 10x Genomics conference call scheduled for?

The conference call will be held at 1:30 PM PT on May 3, 2023.

Where can I listen to the 10x Genomics webcast?

The live audio of the webcast can be found in the 'Investors' section of the 10x Genomics website.

Is there an archive for the 10x Genomics webcast?

Yes, the webcast will be archived and available for replay for at least 45 days after the event.

What type of products does 10x Genomics offer?

10x Genomics offers integrated solutions including instruments, consumables, and software for analyzing biological systems.

10x Genomics, Inc.

NASDAQ:TXG

TXG Rankings

TXG Latest News

TXG Stock Data

1.61B
103.97M
2.17%
94.44%
6.28%
Health Information Services
Laboratory Analytical Instruments
Link
United States of America
PLEASANTON